Ivan Hyep Sells 6,415 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 6,415 shares of the firm’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $18.23, for a total value of $116,945.45. Following the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,649,821.65. This trade represents a 4.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total value of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.21, for a total value of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.17, for a total value of $118,359.38.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $17.78 on Friday. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09. The company has a market capitalization of $970.97 million and a price-to-earnings ratio of -5.61. The business has a 50-day moving average of $12.51 and a 200-day moving average of $11.86.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04. As a group, sell-side analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP lifted its holdings in shares of Bicara Therapeutics by 80.6% in the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after purchasing an additional 2,231,025 shares in the last quarter. Braidwell LP lifted its holdings in shares of Bicara Therapeutics by 8.1% in the first quarter. Braidwell LP now owns 2,162,803 shares of the company’s stock valued at $28,181,000 after purchasing an additional 162,144 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Bicara Therapeutics by 84.0% in the first quarter. Wellington Management Group LLP now owns 1,394,676 shares of the company’s stock valued at $18,173,000 after purchasing an additional 636,708 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after purchasing an additional 180,833 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Bicara Therapeutics by 2,351.0% in the second quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock valued at $4,192,000 after purchasing an additional 432,818 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Piper Sandler assumed coverage on Bicara Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $36.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicara Therapeutics in a research note on Saturday, September 27th. Finally, HC Wainwright decreased their target price on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.86.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.